5 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson

4. BioNTech SE (NASDAQ: BNTX)

Neilson’s Stake Value: $16,641,000
Percent of Kerr Neilson’s 13F Portfolio: 0.38%
Number of Hedge Fund Holders: 17

BioNTech SE (NASDAQ: BNTX) is a German biotechnology company with its headquarters in Mainz. The company specialises in the development and production of active immunotherapies for patient-customized treatment options. 

The company reported total revenues of €345.4 million for the Q3 2020, and increase from the €28.0 million reported during the same period in 2019. For the FY 2020, the company reported total revenues of around €482.3 million compared to €108.6 million reported for the full financial year 2019.

BioNTech SE (NASDAQ: BNTX) reported a net profit of €366.9 million in Q3 FY2021 compared to €58.2 million net loss that was registered in Q3 FY2019. The company reported a net profit of €15.2 million for the full financial year 2020 compared to a net loss of €179.2 million reported in the financial year 2019. 

In March 2021, the biotechnology company made a breakthrough announcement in the fight against COVID-19 after releasing evidence that showed Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) led to lower incidence rates of COVID-19 disease among vaccinated individuals.  The new data confirms another set of recently released data that proved the effectiveness of the vaccine in preventing SARS-CoV-2 infections, COVID-19 cases, reducing hospitalizations, and deaths.  The new set of data is expected to boost the vaccination campaign being undertaken by countries around the world and elevate the success level of the fight against the pandemic.

BioNTech SE (NASDAQ: BNTX) also announced plans by the U.S. Food and Drug Administration to authorize Pfizer Inc and BioNTech SE’s COVID-19 vaccine for adolescents between the age of 12 and 15 years in the coming weeks.